Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial

This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.

Detalles Bibliográficos
Autores principales: Cheng, Matthew, Fowler, Rob, Murthy, Srinivas, Pinto, Ruxandra, Sheehan, Nancy L., Tseng, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425145/
https://www.ncbi.nlm.nih.gov/pubmed/36036936
http://dx.doi.org/10.1001/jamanetworkopen.2022.29236
Descripción
Sumario:This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.

Ejemplares similares